NEW YORK (GenomeWeb) – Agendia said today that French hospital group Unicancer has selected its MammaPrint and BluePrint tests for use in a group of 18 comprehensive cancer centers.
The agreement includes centralized testing performed by Agendia in its CLIA-certified, CAP-accredited Amsterdam lab, as well as the provision of next-gen sequencing MammaPrint BluePrint kits, which hospital labs can run in house.
Marjolaine Baldo, Agendia's commercial vice president, EMEA, said in a statement that Unicancer's adoption of its tests is a "significant milestone."
The company promotes MammaPrint and BluePrint as complementary assays, providing both risk and molecular subtyping information. MammaPrint analyzes 70 genes associated with breast cancer recurrence to provide a binary low or high risk of cancer recurrence to help physicians decide which individuals can forgo chemotherapy. BluePrint includes 80 genes and classifies a patient's breast cancer into one of four functional molecular subtypes.
Agendia received a CE mark for the NGS kit-version of its tests — which uses Agilent Technologies' SureSelect target enrichment system — in March.